Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Comparison of the 20 cases and 40 controls in univariate analysis with conditional logistic regression

From: Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study

  Cases (n= 20) Controls (n= 40) P
Female, n 19 34 0.27
No-low/moderate-high rheumatic disorder activity, n 11/7 20/20 0.67
TJA surgery on affected or matched joint within the last year, n 8 5 0.03†
- of which primary TJA, n/TJA revision, n 5/3 3/2  
- after TNFα-blockers introduction 6 of 8 5 of 5  
- after TNFα-blocker withdrawal ≥5 half-lives 1 of 6 4 of 5 0.08
Previous TJA infection, n 3 0 0.08
- of which same TJA involved, n 2 - -
Main comorbidities, n    
- Diabetes mellitus 2 1 0.26
- Bronchiectasis 0 1 0.99
- Cirrhosis 0 0 1
- Cancer/hemopathy 0 2 0.99
- HIV 0 0 1
- Chronic renal failure 1 2 1
- Hypogammaglobulinemia 1 1 0.88
Current TNFα-blocker:    
- Infliximab/etanercept/adalimumab, n 7/5/8 13/15/12 0.70
- Duration of exposition to the current TNFα- 26.0 ± 24.1 39.0 ± 24.6 0.06
blocker (months) *    
Number of prior TNFα-blockers * 0.5 ± 0.7 0.6 ± 0.7 0.69
Total duration of exposition to any TNFα-blockers (months) * 32.0 ± 25.6 48.6 ± 25.2 0.07
Oral intake of steroids * (mg/d) 9.5 ± 7.3 5.3 ± 3.9 0.02†
Oral intake of steroids ≥10 mg/d, n 7 7 0.06
Intravenous infusion of steroids last year, n 2 1 0.75
Current DMARDs, n    
- Methotrexate 14 26 0.71
- Leflunomide 1 5 0.99
- Azathioprine 0 2 0.40
  1. * mean ± standard deviation; † Results achieving a P value < 0.05 were considered as statistically significant.
  2. DMARDs, disease-modifying anti-rheumatic drugs; TJA, total joint arthroplasty; TNF, tumor necrosis factor.